ORPHA:454836
Avian influenza
Publications
40,119
Trials
38
Interventional, condition-specific
Researchers
1,609
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, infectious disease characterized by variable severity and outcome, ranging from mild upper respiratory tract infection with fever and cough, to influenza-like illness with rapid progression to severe pneumonia, sepsis with shock, acute respiratory distress syndrome and even death. Additional manifestations may include conjunctivitis, nausea, abdominal pain, diarrhea, vomiting, multiple organ dysfunction, and .
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018695
- MeSH:D005585
- UMLS:C0016627
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
40,119 matched papers (22,291 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
38 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
40,119
40,119 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
40,119 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
22,291 in the last 10 years · low confidence
Phrase hits: 40,117 · MeSH hits: 109
Who's working on it?
1,609
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li J7 papers · 2026
Longhu Laboratory of Advanced Immunology, Zhengzhou, Henan, 450046, China; School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China; Henan Key Laboratory of Immunobiology, Zhengzhou, Henan, 450001, China.
Papers in Europe PMC - 02Wang X7 papers · 2026
Institute for Infectious Disease Control and Prevention, Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.
Papers in Europe PMC - 03Günther A5 papers · 2026
Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.
Papers in Europe PMC - 04Li Y5 papers · 2026
Key Laboratory of Applied Biotechnology on Animal Science & Veterinary Medicine of Zhejiang Province, Zhejiang Engineering Research Center for Veterinary Diagnostics & Advanced Technology, Zhejiang International Science and Technology Cooperation Base for Veterinary Medicine and Health Management, Belt and Road International Joint Laboratory for One Health and Food Safety, China-Australia Joint Laboratory for Animal Health Big Data Analytics, College of Veterinary Medicine of Zhejiang A&F University, Hangzhou 311300, China.
Papers in Europe PMC - 05Li Z5 papers · 2026
Shandong Sinder Technology Co., Ltd., Zhucheng, 266100, China.
Papers in Europe PMC - 06Liu J5 papers · 2026
Department of Mathematics and Statistics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Papers in Europe PMC - 07Wang Y5 papers · 2026
College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, People's Republic of China.
Papers in Europe PMC - 08Wille M5 papers · 2026
WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Papers in Europe PMC - 09Yang J5 papers · 2026
Avian Influenza and Newcastle Disease Group, The Pirbright Institute, Woking, GU24 0NF, UK.
Papers in Europe PMC - 10Zhang J5 papers · 2026
College of Animal Science & Technology, Zhong kai University of Agriculture and Engineering, Guangzhou 510225, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
38
interventional trials for this specific condition
38 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 2,031 trials are registered for influenza, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
38 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 96.4th percentile).
low confidence · 96.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
38 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07240558·RECRUITING·Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
Conditions: Influenza (Pandemic) · Avian Influenza · Vaccination·Matched via name phrase
- NCT06842173·RECRUITING·Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
Conditions: Avian Influenza A Virus·Matched via name phrase
- NCT07678619·ENROLLING BY INVITATION·Smart Analysis and Decision-Making for Emerging Infectious Diseases
Conditions: Emerging Infectious Diseases · COVID-19 · Influenza · Mpox (Monkeypox)·Matched via name phrase
Broader category: influenza
2,031
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07352462·NOT YET RECRUITING·Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath
Conditions: Respiratory Infections · COVID-19 · Influenza Virus Infection · Legionella Pneumophila Infections·Matched via name phrase
- NCT04366115·NOT YET RECRUITING·Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Conditions: ARDS · Covid19 · Influenza, Human·Matched via name phrase
- NCT07110532·RECRUITING·pH1N1 Blinded Challenge Study
Conditions: Influenza·Matched via name phrase
- NCT06753474·RECRUITING·A/Texas Flu Challenge
Conditions: Influenza·Matched via name phrase
- NCT07291635·RECRUITING·Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
Conditions: Influenza·Matched via name phrase
- NCT07217639·NOT YET RECRUITING·Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
Conditions: COVID -19 · Influenza A · Influenza B · Respiratory Synctial Virus·Matched via name phrase
- NCT06599658·RECRUITING·COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Conditions: COVID 19 · Influenza · Rheumatoid Arthritis (RA) · Systemic Lupus Erthematosus·Matched via name phrase
- NCT07721649·NOT YET RECRUITING·Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
Conditions: Acute Coronary Syndrome · Heart Failure · Influenza, Human · Cardiovascular Diseases·Matched via name phrase
- NCT07349017·NOT YET RECRUITING·A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)
Conditions: Influenza·Matched via name phrase
- NCT07359287·RECRUITING·Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
Conditions: Angina · Acute Bronchiolitis · Acute Bronchitis · COPD Exacerbation (AECOPD)·Matched via name phrase
- NCT07126652·NOT YET RECRUITING·Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial
Conditions: Antibody Response·Matched via name phrase
- NCT05291676·RECRUITING·Systems Investigation of Vaccine Responses in Aging and Frailty
Conditions: Influenza·Matched via name phrase
- NCT07169318·RECRUITING·First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
Conditions: Influenza·Matched via name phrase
- NCT05108818·RECRUITING·Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
Conditions: Influenza, Human·Matched via name phrase
- NCT07420985·RECRUITING·Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
Conditions: Influenza · Acute Respiratory Viral Infection·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Avian influenza"
MeSH descriptor terms unioned into the query: Influenza in Birds
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Avian influenza" OR "Influenza in Birds"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 38 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"influenza"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (40119) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T16:44:20.638Z
